MetaCap

Assembly Biosciences (ASMB) vs Gyre Therapeutics (GYRE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Assembly Biosciences (ASMB) has outperformed Gyre Therapeutics (GYRE) over the past year, losing 42.4% versus a loss of 44.2%. Over five years, ASMB leads with a -21.3% price change compared with -77.5% for GYRE. Gyre Therapeutics is the larger company by market cap ($460.8 million vs $454.4 million), about 1.0 times the size, while Assembly Biosciences is growing revenue faster (+153.5% vs +10.2%).

Gyre Therapeutics converts more of its revenue into profit, with a net margin of 8.5% versus -8.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ASMB-42.36%GYRE-44.24%
+19%-17%-53%
Nov 21, 20251 yearNov 20, 2026
ASMB-19.60%GYRE-78.58%
+59%-16%-92%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ASMB versus GYRE key metrics
MetricASMBGYRE
Share price$22.19$4.21
Market cap$454.39M$460.79M
1-day change-1.38%-6.86%
YTD return-34.75%-40.37%
1-year return-42.36%-44.24%
5-year return-21.31%-77.55%
P/E ratio (TTM)29.59—
Forward P/E—70.17
EPS (TTM)$0.75$-0.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$72.30M$116.59M
Revenue growth (YoY)+153.52%+10.24%
Net income (latest FY)$-6.12M$9.88M
Gross margin—95.35%
Operating margin-16.76%9.85%
Net margin-8.47%8.47%
52-week high$39.65$9.14
52-week low$19.20$3.97
Distance from 52-week high-44.04%-53.94%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+130.73%+343.47%
Average volume309.38K181.04K
Shares outstanding20.48M109.45M
Employees73625
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Gyre Therapeutics is more profitable, keeping 8.5 cents of every revenue dollar as net income versus -8.5 cents for Assembly Biosciences.
  • Assembly Biosciences grew revenue faster in its latest fiscal year (+153.52% vs +10.24%).

About Assembly Biosciences

ASMB stock →

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.

Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees

About Gyre Therapeutics

GYRE stock →

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees

ASMB vs GYRE FAQ

Which is bigger, Assembly Biosciences or Gyre Therapeutics?

Gyre Therapeutics (GYRE) is larger, with a market capitalization of $460.79M compared with $454.39M for Assembly Biosciences (ASMB).

Which stock has performed better over the past year, ASMB or GYRE?

ASMB returned -42.36% over the past 12 months, compared with -44.24% for GYRE (price return, excluding dividends). Past performance does not predict future results.

Are Assembly Biosciences and Gyre Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons